IL1B and liver dysplastic nodule: In vivo short‐term therapy of diabetic DBA/2J mice with an anti‐IL1‐β antibody for 4 weeks prevented an increase in serum FetA and considerably decreased urinary tumor necrosis alpha (TNF‐α), a known risk factor for DN progression.